No se han encontrado coincidencias con Kapitza,Christoph, pero utilizando en su lugar Kapitza Christoph...
Resultados globales: 1 registros encontrados en 0.02 segundos.
Artículos, Encontrados 1 registros
Artículos Encontrados 1 registros  
1.
8 p, 1.1 MB Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial / Wysham, Carol (Rockwood Clinic, Spokane, Washington) ; Bonadonna, Riccardo C. (, Department of Clinical and Experimental Medicine, University of Parma) ; Aroda, Vanita R. (Medstar Health Research Institute, Hyattsville, Maryland) ; Puig Domingo, Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Kapitza,Christoph (Profil Institute, Neuss, Germany) ; Stager, William (Sanofi, Bridgewater, New Jersey) ; Yu, Christine (Sanofi, Bridgewater, New Jersey) ; Niemoeller, Elisabeth (Sanofi, Frankfurt, Germany) ; Souhami, Elisabeth (Sanofi, Paris, France) ; Bergenstal,Richard M. (International Diabetes Center, Park Nicollet Health Services, Minneapolis, Minnesota) ; Universitat Autònoma de Barcelona
Aims: To assess the impact of baseline characteristics on clinical outcomes in the LixiLan-L trial, a randomized open-label trial designed to evaluate the efficacy and safety of iGlarLixi, a novel fixed-ratio combination of insulin glargine 100 U (iGlar) plus lixisenatide, in comparison with iGlar over 30 weeks in a population of patients with type 2 diabetes mellitus (T2DM) inadequately controlled on a previous regimen of basal insulin alone or in combination with 1 or 2 oral glucose-lowering drugs. [...]
2017 - 10.1111/dom.12961
Diabetes, Obesity and Metabolism, Vol. 19 (2017) , p. 1408-1415  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.